

# SmartPA Criteria Proposal

<b>Drug/Drug Class:</b>	Corticosteroids, Ophthalmic "Soft" PDL Edit
<b>First Implementation Date:</b>	July 11, 2019
<b>Proposed Date:</b>	March 18, 2021
<b>Prepared For:</b>	MO HealthNet
<b>Prepared By:</b>	MO HealthNet/Conduent
<b>Criteria Status:</b>	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

## Executive Summary

**Purpose:** The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

**Why Issue Selected:** Topical corticosteroids are effective in reducing anterior segment inflammation but are associated with adverse drug reactions including elevation of intraocular pressure and cataract formation. Newer "soft" ophthalmic corticosteroids have been developed with improved therapeutic indices through retrometabolic drug design. The retrometabolic drug design principles appear to achieve the necessary balance between solubility/lipophilicity, tissues distribution, glucocorticoid receptor binding, and metabolic deactivation to be effective as a topical ophthalmic steroid. The "soft" steroids are safe and effective in treating a wide variety of ocular inflammatory conditions including giant papillary conjunctivitis, seasonal allergic conjunctivitis, and uveitis as well as in the treatment of ocular inflammation and pain following cataract surgery. Clinical studies have confirmed the retrometabolic design of "soft" steroids minimized adverse reactions such as cataract formation and intraocular pressure elevation.

Total program savings for the PDL classes will be regularly reviewed.

<b>Program-Specific Information:</b>	<b>Preferred Agents</b>	<b>Non-Preferred Agents</b>
	<ul style="list-style-type: none"> <li>Durezol®</li> <li><b>Lotemax® 0.5% Gel</b></li> </ul>	<ul style="list-style-type: none"> <li>Alrex®</li> <li><b>Eysuvis™</b></li> <li>Inveltys™</li> <li>Lotemax® 0.5% Oint/Susp</li> <li>Lotemax® SM</li> <li>Loteprednol</li> </ul>

- Type of Criteria:**  Increased risk of ADE  Preferred Drug List  
 Appropriate Indications  Clinical Edit
- Data Sources:**  Only Administrative Databases  Databases + Prescriber-Supplied

## Setting & Population

- Drug class for review: Corticosteroids, Ophthalmic “Soft”
- Age range: All appropriate MO HealthNet participants

## Approval Criteria

- Failure to achieve desired therapeutic outcomes with trial on **2** or more preferred agents
  - Documented trial period of preferred agents **OR**
  - Documented ADE/ADR to preferred agents

## Denial Criteria

- Therapy will be denied if all approval criteria are not met

## Required Documentation

Laboratory Results:  
MedWatch Form:

  

Progress Notes:  
Other:

  

## Disposition of Edit

Denial: Exception Code “0160” (Preferred Drug List)  
Rule Type: PDL

## Default Approval Period

1 year

## References

1. LOTEMAX® [package insert]. Bridgewater, NJ: Bausch and Lomb.; Revised: 09/2016.
2. Lippincott, Williams, Wilkins. PDR Electronic Library, Montvale NJ; 2021.
3. USPDI, Micromedex; 2021.
4. Facts and Comparisons eAnswers (online); 2021 Clinical Drug Information, LLC.
5. Evidence-Based Medicine and Fiscal Analysis: “Ophthalmic Soft Corticosteroids – Therapeutic Class Review”, Conduent Business Services, L.L.C., Richmond, VA; March 2021.
6. Evidence-Based Medicine Analysis: “Corticosteroids, Ophthalmic Soft Steroids”, UMKC-DIC; February 2021.